MedTrace Logo

A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes

NCT01134224 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2013-11-27

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to evaluate the blood glucose-lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

insulin degludec/insulin aspart

0.4 U/kg body weight injected subcutaneously (under the skin) once

DRUG

insulin degludec/insulin aspart

0.6 U/kg body weight injected subcutaneously (under the skin) once

DRUG

insulin degludec/insulin aspart

0.8 U/kg body weight injected subcutaneously (under the skin) once

DRUG

biphasic insulin aspart 30

0.4 U/kg body weight injected subcutaneously (under the skin) once

DRUG

biphasic insulin aspart 30

0.6 U/kg body weight injected subcutaneously (under the skin) once

DRUG

biphasic insulin aspart 30

0.8 U/kg body weight injected subcutaneously (under the skin) once

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01134224 on ClinicalTrials.gov